AUTHORS
Shengqin Su, PhD, Ajay Subramanian2, Jamie E Flerlage, MD, MS3, Cedric Rossi, MD, PhD4, Jan Boegeholz, MD5, Stefan Alig, MD6, Sheren Younes, MD, PhD7, Oscar Silva, MD8, Sandra Luna-Fineman, MD9, Timothy Flerlage10, Heidi Mocikova, MD11, Alice Sykorova, MD, PhD12, Vit Karel Prochazka, MD, PhD, Prof.13, Cristiane Milito14, Pamela Allen, MD15, Darina Paulino16, Alan Ramsay17, Chelsea C. Pinnix, MD, PhD18, Francisco Vega Sr, MD PHD19, Raphael Steiner, MD20, Burton Appel, MD, MBA21, Natalie Park22, Richard Hoppe, MD23, Ranjana Advani, MD24, Yasodha Natkunam, MD, PhD25, Ash A. Alizadeh, MD, PhD26, Michael S Binkley, MD, MS27
AFFILIATIONS
1 Stanford University School of Medicine, Stanford, California, United States
2 Stanford University School of Medicine, Stanford, California, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States, University of Rochester, Rochester, New York, United States
4 Stanford University, Stanford, California, United States, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France
5 University Hospital Zürich, Zürich, Switzerland
6 Stanford University, Stanford, California, United States
7 Stanford University School of Medicine, Stanford, California, United States
8 Stanford University School of Medicine, Stanford, California, United States
9 University of Colorado Anschutz Medical Center, Aurora, Colorado, United States
10 University of Rochester, Rochester, New York, United States
11 Charles University, Prague, Czech Republic
12 Charles University, Hradec Kralove, Czech Republic
13 Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
14 Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
15 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
16 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
17 University College London Hospitals NHS Foundation Trust, London, United Kingdom
18 MD Anderson Cancer Center, Houston, Texas, United States
19 MD Anderson Cancer Center, Houston, Texas, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Joseph M. Sanzari Children’s Hospital, Hackensack, New Jersey, United States
22 Stanford University School of Medicine, Stanford, California, United States
23 Stanford University School of Medicine, Stanford, California, United States
24 Stanford University, Stanford, California, United States
25 Stanford University School of Medicine, Stanford, California, United States
26 Stanford University, Stanford, California, United States
27 Stanford University School of Medicine, Stanford, California, United States
ABSTRACT
Introduction: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma (HL) distinct from classic Hodgkin lymphoma (cHL), with sparse CD20+ lymphocyte-predominant (LP) tumor cells in a dominant immune cell infiltrate. We previously defined three lymphocyte-predominant ecotypes (LPEs) that resolved the microenvironmental heterogeneity of NLPHL (Subramanian and Su, Nat Commun, 2025). Building on that framework, we characterized NLPHL relative to cHL along two axes: tumor microbial profiles derived from RNA-seq, and tumor genotype recovered noninvasively from circulating tumor DNA (ctDNA). We hypothesized that NLPHL has a microbial profile and mutational landscape distinct from cHL.
Methods: We analyzed two independent cohorts. First, we collected FFPE tumors from 199 patients with cHL and 186 patients with NLPHL from multiple institutions in Europe and North America. Bulk RNA-seq was performed on the tumors, and the data were processed through a single Kraken2/Bracken pipeline applied identically to both subtypes. The community structure between NLPHL and cHL was compared by PERMANOVA on Bray–Curtis dissimilarities and within-subtype heterogeneity by a permutation test for multivariate dispersion. Second, we isolated plasma ctDNA and matched peripheral-blood leukocyte DNA from 22 NLPHL patients and performed hybrid-capture targeted sequencing (BLYMv2 panel, 772 kb). SNVs/indels were called with Mutect2, annotated with SnpEff, and filtered for artifacts and clonal hematopoiesis; CNVs were called with CNVkit. Tumor fraction was estimated as twice the median variant allele frequency (VAF) of confidently identified SNVs in samples with ≥3 eligible SNVs.
Results: Among 385 tumors, the microbiome composition differed significantly between NLPHL and cHL (P=1×10⁻⁴ on Bray–Curtis dissimilarities). NLPHL showed greater within-cohort heterogeneity than cHL (mean distance to centroid 0.625 vs 0.587; P=4×10⁻4). Nineteen taxa outside our contaminant-genus list met criteria for enrichment in NLPHL, but notably did not include Rothia or Moraxella spp as reported by others. In the ctDNA cohort, 20/22 samples yielded reportable tumor fraction (median, 3.6%; IQR, 2.4–4.7%). SGK1 was the most recurrently mutated gene (4/20, 20%), highlighting germinal-center/aberrant somatic hypermutation (aSHM) programs, followed by recurrent NF-κB–activating lesions in NFKBIA (3/20, 15%), with additional NF-κB pathway mutations in MYD88 (1/20, 5%) and the negative regulator ZC3H12A (1/20, 5%). Copy-number alterations were predominantly losses, most commonly 6p (MHC-I region; 7/22, 32%) and 6q (3/22, 14%), with recurrent 21q amplification (3/22, 14%).
Conclusions: Across 385 tumors and an independent 22-patient plasma cohort, we defined microbial profiles and the ctDNA mutational landscape of NLPHL. Microbial profiles were more heterogeneous in NLPHL than cHL. ctDNA genotyping revealed an SGK1-enriched germinal-center/aSHM genotype that distinguished NLPHL from cHL while converging on shared NF-κB dependencies. These findings support plasma ctDNA for noninvasive genotyping of NLPHL, and motivate microbiome studies to more fully characterize the tumor microenvironment.
DISCLOSURES
Shengqin Su, PhD: No relevant conflicts of interest to declare.